Phase 2

Ifinatamab Deruxtecan (previously known as DS-7300a), a B7-H3-directed antibody-drug conjugate being developed by Daiichi Sankyo and Merck & Co. (known as MSD outside of the United States and Canada), could offer a First-in-Class option for patients diagnosed with extensive-stage small cell lung cancer (ES-SCLC) following platinum-based chemotherapy.

AbbVie Showcases Promising Phase 2 Data for Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer at SGO 2026

AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has approved an Investigational New Drug (IND) application for SKB105 (also known as CR-003 and PR-023), integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC) being developed by Sichuan Kelun-Biotech Biopharmaceutical, for the treatment of advanced solid tumors.

TUB-040: A Next-Generation NaPi2b-Targeted ADC for Ovarian and Lung Cancer

Results from the phase 2 dose optimization part of the REJOICE-Ovarian01 phase 2/3 trial (NCT06161025) showed that raludotatug deruxtecan (R-DXd, DS-6000a; see ADC Drugmap), a specifically engineered, potential first-in-class CDH6-directed antibody drug conjugate, discovered by Daiichi Sankyo and jointly developed by Daiichi Sankyo and Merck & Co (known as MSD outside of the United States and Canada), demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer.

Lonza's Synaffix has entered into a licensing agreement with Qurient Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload antibody-drug conjugate (ADC).

Datopotamab deruxtecan (datopotamab deruxtecan-dlnk in the U.S. only; Datroway®; Daiichi Sankyo and AstraZeneca; see ADC Drug Map) has been approved by the U.S. Food and Drug Administration (FDA)

Disitamab Vedotin Gains Approval in China for its Third Indication

Shanghai (China) base CStone Pharmaceuticals has submitted a Phase 1b clinical trial application in Australia for CS5001, a receptor tyrosine kinase-like orphan receptor 1 (ROR1-) targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for the treatment of Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL).